Clinical features, treatment, and outcomes of anti-PD-1/PD-L1 immune checkpoint inhibitors induced dermatomyositis

During anti-PD-1/PD-L1 therapy, closely monitor patients' cutaneous and muscular symptoms to detect DM early. For diagnosed DM patients, implement timely interventions according to symptom severity.